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Summary 
The bax gene promoter region contains four motifs 
with homology to consensus p53-binding sites. In co- 
transfection assays using p53-deficient tumor cell 
lines, wild-type but not mutant p53 expression plas- 
mids transactivated a reporter gene plasmid that uti- 
lized the bax gene promoter to drive transcription of 
chloramphenicol acetyltransferase. In addition, wild- 
type p53 transactivated reporter gene constructs con- 
taining a heterologous minimal promoter and a 39-bp 
region from the bax gene promoter in which the p53- 
binding site consensus sequences reside. Introduc- 
tion of mutations into the consensus p53-binding site 
sequences abolished p53 responsiveness of reporter 
gene plasmids. Wild-type but not mutant p53 protein 
bound to oligonucleotides corresponding to this re- 
gion of the bax promoter, based on gel retardation 
assays. Taken together, the results suggest that bax 
is a p53 primary-response gene, presumably involved 
in a p53-regulated pathway for induction of apoptosis. 
Introduction 
Inactivation of the p53 tumor suppressor gene occurs in 
over half of all human tumors, implying that loss of this 
gene represents a fundamentally important step in the 
pathogenesis of cancer (Hollstein et al., 1991; Vogelstein 
and Kinzler, 1992). The p53 protein functions at least in 
part as a transcriptional regulator and can transactivate cel- 
lular genes through sequence-specific interactions with 
DNA containing the sequence 5'-PuPuPuC(A/T)(T/A)G Py- 
PyPy-3', typically in the context of two such sequence mo- 
tifs separated by 0-13 bp (EI-Deiry et al., 1992; Kern et 
al., 1992; Sch&rer and Iggo, 1992). At least two important 
events are regulated by p53 in connection with its function 
as a tumor suppressor. First, p53 has been shown to in- 
duce cell cycle arrest at the GI/S border (Mercer et al., 
1990). This action of p53 has been ascribed to its ability 
to induce expression of a cellular gene WAF1/CIP1 that en- 
codes a 21 kDa inhibitor of G1 cyclin-dependent kinases 
(EI-Deiry et al., 1993; Harper et al., 1993). Second, p53 
can induce apoptosis. Expression of wild-type p53 in some 
p53-deficient umor cell lines results in spontaneous cell 
death (Yonish-Rouach et al., 1991; Shaw et al., 1992). In 
other p53-deficient umor cell lines, however, the mere 
restoration of p53 activity is insufficient to trigger apoptosis, 
but does render cells relatively more sensitive to induction 
of apoptosis by radiation and DNA-damaging chemothera- 
peutic drugs (Lowe et al., 1993a; Bristow et al., 1994; 
Fisher 1994). In this regard, it has been shown that the 
relative amounts of p53 transcriptional activity increase 
and levels of p53 protein become elevated through post- 
transcriptional mechanisms in cells exposed to radiation 
and DNA-damaging drugs, suggesting that p53 partici- 
pates in a cellular system involved in genome surveillance 
and DNA repair (Lu and Lane, 1993; Zhan et al., 1993). 
The specific roles played by p53 in this process presumably 
include the arrest of cycling cells before S-phase to allow 
for repair of damaged DNA prior to DNA replication and 
the induction of apoptosis for cases in which the DNA 
damage is too severe to be properly repaired. Loss of p53 
may thus contribute to the genomic instability common 
in tumor cells, both by allowing tumor cells to replicate 
damaged DNA, which would fix errors in the genome, and 
by promoting the survival of cells such that genomic alter- 
ations accumulate with time. 
The effects of p53 on cell cycle arrest and apoptosis 
appear to be separable functions. For example, in tumor 
cell lines lacking p53 in which inducible restoration of p53 
function results in cell cycle arrest and apoptosis, gene 
transfer-mediated elevations in the apoptosis-blocking 
Bcl-2 protein have been shown to interfere with p53- 
induced apoptosis without impairing p53-induced GI/S ar- 
rest (Wang et al., 1993; Selvakumaran et al., 1994; Ryan 
et al., 1994). Studies of p53-deficient transgenic mice (p53 
"knockouts") have also demonstrated that p53 is required 
for the induction of apoptosis by y radiation and by some 
DNA-damaging drugs in thymocytes, which are mostly 
noncycling cells in G0/G1 phase in vivo (Lowe et al., 
1993b; Clarke et al., 1993). Loss of p53 function has also 
been shown to delay apoptosis resulting from growth fac- 
tor deprivation in hemopoietic cells deprived of lympho- 
kines, but it does not prevent G0/G1 arrest (Gottlieb et al., 
1994). Finally, the importance of apoptosis regulation for 
in vivo suppression of tumor formation by p53 has been 
underscored recently by studies of transgenic mice in 
which tumor development was associated with loss of p53 
and decreased rates of cell death rather than with in- 
creased rates of cell proliferation (Symonds et al., 1994). 
At present it remains unclear how p53 induces apoptosis. 
Recently, however, we obtained evidence that restoration 
of p53 in a murine leukemia cell, M1, was associated with 
increases in bax mRNA and protein. Furthermore, these 
increases in bax gene expression were accompanied by 
simultaneous decreases in the steady-state levels of bcl-2 
mRNA and protein (Miyashita et al., 1994a; Selvakumaran 
et al., 1994). Bcl-2 and Bax are homologous proteins that 
have opposing effects on cell life and death, with Bcl-2 
serving to prolong cell survival and Bax acting as an accel- 
erator of apoptosis (reviewed by Reed, 1994). The Bcl-2 
and Bax proteins can form heterodimers in cells (Oltvai 
et al., 1993). Furthermore, the interaction of Bcl-2 with Bax 
appears to be important for the ability of Bcl-2 to block 
cell death, based on analysis of Bcl-2 mutants (Yin et al., 
1994; Sato et al., 1994). The effects of p53 on bcl-2 gene 
expression may be mediated at least in part by a cis-acting 
p53 negative-response lement located in the 5' untrans- 
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Figure 1. Nucleotide Sequence of the Human bax Gene Promoter 
and 5'UTR 
The nucleotide sequence of the bax gene corresponding tothe first 972 
bp upstream of the translation i itiation site is shown. The approximate 
transcription start site is indicated by an arrow. The perfect (10 of 10 
matches) p53-binding site consensus equence is boxed, and the 
three imperfect p53-binding sites are either underlined or overlined 
with dashes. The TATAA box is double underlined. The CACGTG 
motifs are single underlined. 
lated region (5'UTR) of the bcl-2 gene (Miyashita et al., 
1994b). 
To investigate the mechanisms by which p53 regulates 
bax gene expression, we molecularly cloned and deter- 
mined the partial DNA sequence of the human bax gene. 
Functional analysis of the bax gene promoter indicates 
that this apoptosis-inducing ene is a direct target of p53. 
These findings thus provide the first example of a pro- 
apoptotic gene that is directly regulated by p53. 
Results 
The Human bax Gene Promoter Contains Potential 
p53-Binding Sites 
The human bax gene was cloned and the DNA sequence 
was determined for the first -1000 bp upstream of the 
translation intitiation site, corresponding to the presump- 
tive promoter and 5'UTR of the bax gene (Figure 1). A 
TATAA box is located 398 bp upstream from the open 
reading frame in the human gene. A transcription start 
site was mapped by primer extension to a position -22  
bp downstream of the TATAA homology element. Within 
the 5'UTR of the bax gene are four CACGTG motifs that 
represent potential binding sites for several transcription 
factors, including Myc and its homologs Max, Mad, and 
Mxi-1, as well as upstream stimulatory factor and related 
transcription factors (Blackwood and Eisenman, 1991; 
Zervos et al., 1993; Ayer et al., 1993; Pognonec et al., 1992). 
Located - 70 bp 5' of the TATAA box, at positions -486 
bp to -448 bp in the bax gene, are one perfect and three 
imperfect consensus sites for p53 binding (Figure 1). In 
the bax gene promoter, the perfect 10-bp consensus site 
(-474 bp to -465 bp) is flanked on the 5' side by a se- 
quence that shares 7 of 10 matches with the consensus 
sequence, including a stretch of 7 of 7 matches in the 
core of this motif. This second potential p53-binding site 
is separated from the perfect site by a single nucleotide. 
On the 3' side, separated from the perfect p53-binding site 
by 0 bp or 6 bp, respectively, are two additional imperfect 
10-bp motifs that have either 7 of 10 or 8 of 10 matches 
with the consensus sequence. 
The bax Gene Promoter Is p53 Responsive 
To explore the functional significance of the potential p53- 
binding sites identified in the bax gene promoter, reporter 
gene plasmids were constructed that contained the region 
of bax from -687 bp to -318 bp, which includes the TATAA 
box and transcription start site as well as the upstream 
p53 consensus sites. This DNA segment was subcloned 
upstream of chloramphenicol acetyltransferase (CAT) in 
a promoterless plasmid. Cotransfection assays were then 
performed in which the bax-CAT plasmid was introduced 
into p53-deficient human tumor cell lines with expression 
plasmids encoding wild-type p53, a mutant inactive form 
of p53 (His-179-*Glu), or no p53 protein. 
In H358 human lung cancer cells, cotransfection with 
plasmid DNA encoding wild-type p53 protein resulted in 
strong transactivation of the bax gene promoter, with a 
60-fold increase in CAT activity compared with cells co- 
transfected with plasmid encoding the mutant p53(179) or 
no p53 protein (Figure 2A). Similarly, wild-type but not 
mutant p53 strongly transactivated the bax-CAT plasmid 
by - 30-fold in the p53-deficient osteosarcoma line Saos-2 
(Figure 2B). Transaction by wild-type p53 of the bax-CAT 
plasmid was also seen in the human cervical cancer line 
HeLa, which has reduced p53 activity in part owing to the 
presence of E6 protein from human papilloma virus, as 
well as in a p53-deficient human prostate cancer line, Tsu- 
prt (Figure 2B). Taken together, these data indicate that 
p53 can be a strong transactivator of the bax promoter in 
a variety of types of human tumor lines. 
The Potential p53-Binding Sites in bax (-486 bp to 
-448 bp) Are Sufficient for Transactivation 
To begin to delineate the minimal region within the bax 
gene responsible for transactivation by p53, a 94-bp Ddel- 
Ddel fragment from the bax gene promoter (-508 bp to 
-415 bp) that contains the four potential p53-binding sites 
was subclened upstream of a minimal promoter in the plas- 
mid pA10-CAT. In addition, a mutant version of this region 
from the bax promoter, with point mutations in 3 of the 4 
potential p53-binding sites, was created by site-directed 
mutagenesis. When cotransfected into H358 cells with 
wild-type p53, CAT constructs containing this 94-bp frag- 
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Figure 2. The bax Gene Promoter Is p53 Responsive 
A SmaI-Sacl restriction fragment containing -687 bp to -318 bp of the 
human bax gene was subcloned upstream of CAT in the promoterless 
plasmid pUCSVOCAT and was cotransfected into various p53-deficient 
tumor cells with pCMV-J~-gal and either pCMV-p53~t (W), pCMV- 
p53179 (M), or pRc/CMV (minus ign) plasmid DNAs. CAT activity was 
measured 2days later and was normalized relative to J~-gal. Previous 
studies howed that p53 does not influence the activity of the pCMV- 
I~-gat plasmid (Miyashita et al., 1994b). In (A), H358 lung carcinoma 
cells were employed for reporter gene assays (mean standard evia- 
tion (mean _+ SD, n = 3). The bax gene promoter egion tested is 
shown schematically atthe top. In (B), Saos-2 osteosarcoma, HeLa 
cervical cancer, and TSU-prl prostate cancer cells were employed for 
reporter gene assays. The data are representative of 2 of 2 experi- 
ments. 
ment were transactivated by - 6- to 8-fold compared with 
cells that received plasmids encoding mutant p53(179) or 
no p53 protein. In contrast, CAT reporter gene plasmids 
containing mutations in the potential p53-binding sites 
were unresponsive to p53 (Figure 3). Thus, the -508 bp 
to -415 bp segment of the bax gene promoter is sufficient 
to confer p53-dependent regulation on a heterologous pro- 
moter. 
The four potential p53-binding sites in the bax gene pro- 
moter reside within a 39-bp region (-486 bp to -448 bp). 
Therefore, we subcloned oligonucleotides comprising this 
sequence upstream of a minimal promoter in pA10-CAT. 
In cotransfection experiments, wild-type p53 strongly 
transactivated ( -10-  to 15-fold) CAT constructs con- 
taining this 39-bp sequence. In contrast, cotransfection of 
this CAT reporter gene construct with plasm ids expressing 
the inactive p53(179) protein or no p53 protein resulted 
in little CAT production. Thus, this 39-bp element from the 
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Figure 3. The -486 bp to -448 bp Region of the bax Gene Promoter 
Is Sufficient for Conferring p53-Positive Responsiveness on a Heterol- 
ogous Promoter 
Various fragments of the bax gene promoter were subcloned upstream 
of a minimal promoter in the plasmid pA10CATBS and were cotrans- 
fected into H358 cells with plasmids that encode wild-type p53 (W), 
mutant p53 (M), or no p53 (minus ign) protein. CAT activity was mea- 
sured 2 days later and was normalized relative to J~-gal (mean _+ SD, 
n = 3). The region of the bax promoter analyzed is shown schemati- 
cally at the top. The asterisk indicates amutant version of the protein 
with alterations inpotential p53-binding sites (see Experimental Proce- 
dures). 
bax gene is sufficient for p53-mediated transactivation. 
Reporter gene constructs that contained only portions of 
this 39-bp element were far less effective with regards to 
p53-mediated transactivation. 
p53 Binds to the bax Gene p53 Response Element 
In Vitro 
Gel retardation assays were performed to determine 
whether the p53 protein can potentially bind to oligonucle- 
otides containing the 39-bp (-486 bp to -448 bp) sequence 
corresponding to the p53-response element in bax. For 
these experiments, wild-type p53 and mutant p53(179) 
proteins were produced in Sf9 cells using recombinant 
baculoviruses, and extracts from these cells were incu- 
bated with 32P-labeled DNA probes containing either the 
39-bp bax gene sequence or a mutant version containing 
nucleotide substitutions in 3 of the 4 p53-binding site mo- 
tifs. Antibodies directed against p53 were also included 
in some samples to help stablize the in vitro interaction 
of p53 with target DNAs (Hupp et al., 1992). As shown in 
Figure 4, proteins present in the Sf9 cells used to produce 
p53 proteins bound nonspecifically to both the wild-type 
and mutant DNA probes, irrespective of the presence or 
absence of p53 proteins (lanes 2-9). However, when the 
wild-type p53 protein was incubated with wild-type DNA 
probe, a complex with shifted gel mobility was detected 
(Figure 4, lane 4). Moreover, when the combination of wild- 
type p53 protein, wild-type DNA probe, and anti-p53 anti- 
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Figure 4. p53 Can Bind In Vitro to an Oligonucleotide Probe Repre- 
senting the bax Gene Region 
Lysates prepared from uninfected Sf9 cells or cells infected with re- 
combinant baculoviruses encoding wild-type p53 (wt, top line) or mu- 
tant 179 p53 (rnt, top line) were incubated with 32P-labeled oligonucleo- 
tide (oligo, bottom line) DNA probes containing the -486 bp to -448 bp 
region of bax (wt, bottom line) or a mutant version with four nucleotide 
substitutions (mt, bottom line), together with (plus sign) or without (mi- 
nus sign) monoclonal ntibodies (Abs) against p53 as indicated. DNA- 
protein complexes were size fractionated innondenaturing polyacryl- 
amide gels and were detected by autoradiography. The open and 
closed arrows indicate he presence of the shifted and supershifted 
complexes, respectively. In lane 1, the DNA probe was subjected to 
electrophoresis directly without prior incubation with cell lysates or 
antibodies. 
body was employed, the band detected in lane 4 of Figure 
4 was replaced by a supershifted band (lane 7). In contrast, 
substitution of mutant p53 for wild-type p53 protein, mutant 
DNA probe for the wild-type sequence, or different mono- 
clonal antibodies for the anti-p53 antibodies resulted in a 
failure to detect mobility-shifted complexes in these gel 
retardation assays (Figure 4, lanes 8-9; data not shown). 
Discussion 
p53 protein suppresses tumor formation in vivo at least 
in part through its ability to induce cell death (Symonds 
et al., 1994). In addition, loss of p53 appears to play a 
significant role in the treatment of cancer, based on clinical 
correlative studies (Thor et al., 1992; Sun et al., 1992; 
Visakorpi et al., 1992). Presumably, the reason for the 
prognostic significance of p53 loss can be explained in part 
by the following observations: nearly all cytotoxic drugs 
commonly used in the treatment of cancer, as well as radi- 
ation, have in common the ability to induce tumor cell 
death through apoptosis (reviewed by Reed, 1994); and 
the relative sensitivity of tumor cells to induction of 
apoptosis by drugs and radiation is modulated by p53 in 
many cases (reviewed by Fisher, 1994). Until now, the 
mechanisms by which p53 loss renders tumor cells more 
resistant o induction of apoptosis by anticancer drugs and 
radiation have remained obscure. The data presented 
here, however, suggest that one contributor may be the 
loss of p53-induced elevations in bax gene expression. In 
this regard, it was reported recently that p53-mediated 
induction of new gene expression is not obligatory for trig- 
gering apoptosis in response to UV radiation in a pituitary 
tumor cell line inasmuch as actinomycin D and cyclohexi- 
mide did not impair the process (Caellas et al., 1994). 
When examined within the context of our findings on p53- 
mediated regulation of bcl-2 and bax gene expression (Mi- 
yashita et al., 1994a, 1994b; Selvakumaran et al., 1994), 
this recent report suggests that p53-stimulated elevations 
in bax gene expression are not required for apoptosis, but 
it does not exclude a potentially important role for p53- 
induced reductions in bcl-2 expression. However, the 
extent to which p53-mediated transactivation of gene ex- 
pression is not required for p53-dependent apoptotic re- 
sponses may be cell-type specific. For example, we have 
shown that most types of neuronal cells contain what ap- 
pear to be relatively high levels of Bax protein (Miyashita 
et al., 1994a; Krajewski et al., 1994). It could therefore be 
that sufficient levels of Bax protein are already present in 
some types of cells, such as the pituitary tumor cell line 
employed recently to explore the issue of requirements 
for new gene expression for p53-induced apoptosis (Cael- 
les et al., 1994). 
Regardless of whether there exists an obligatory re- 
quirement for stimulation of bax gene expression in all 
types of cells in which p53 has been shown to induce 
apoptosis, it seems reasonable to propose that p53- 
mediated elevations in Bax protein levels would at least 
render cells more susceptible to apoptotic cell death. The 
relative ratio of Bax and Bcl-2 proteins has been hypothe- 
sized to be a major determinant of cellular vulnerability to 
apoptosis (Oltvai et al., 1993). Based on studies with bcl-2 
knockout mice and experiments using antisense ap- 
proaches to reduce bcl-2 expression, it appears that low- 
ering the ratio of Bcl-2 to Bax may often be insufficient, by 
itself, to trigger apoptosis, but it does render cells relatively 
more sensitive to induction of cell death by various apop- 
totic stimuli, ncluding 7 radiation and cytotoxic anticancer 
drugs (Nakayama et al., 1993; Veis et al., 1993; Kitada et 
al., 1993, 1994). Likewise, p53 probably does not"induce" 
apoptosis per se but rather adjusts the relative sensitivity 
of cells so that apoptosis can be triggered more easily in 
response to stimuli that activate the endogenous cell death 
pathway or when cells are confronted with clashes in their 
signals for cell cycle control (Wu and Levine, 1994; Fisher, 
1994). Thus, as pertains to anticancer drugs and radiation, 
for example, elevations in p53 activity have been shown 
to shift the dose-response curve to the left, allowing for 
induction of tumor cell death by relatively lower concentra- 
tions of drugs or lower doses of radiation. In those cases 
for which the mere reintroduction of functional p53 into a 
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p53-deficient cell was shown to cause cell death and no 
additional stimulus (such as radiation or exposure to a 
DNA-damaging drug) was required, it should be borne in 
mind that some types of neoplastic cells may have high 
rates of spontaneous DNA damage owing to crippled DNA 
repair machinery, generation of DNA-damaging reactive 
oxygen species due to altered cellular metabolism, or 
other causes. Therefore, taken together, the data pre- 
sented here and elsewhere are consistent with a model 
in which the induction of elevations in p53 activity by DNA- 
damaging agents or other means can lower the resistance 
of cells to apoptotic stimuli through p53-mediated effects 
on bck2 and bax gene expression. These p53-induced 
changes in bcl-2 and bax gene expression would alter the 
ratio of Bcl-2 and Bax proteins, placing the cells into a 
state of enhanced susceptibilty to apoptosis. 
Though the bax gene promoter clearly has the potential 
to respond to p53, the findings presented here do not ex- 
clude the possibil ity that other cis-acting elements within 
the bax gene can mediate p53-independent ransactiva- 
tion of this gene or can modulate the influence of p53 on 
it. In this regard, our previous analysis of tissues from p53 
knockout mice using immunoblott ing and immunohisto- 
chemical techniques demonstrated that Bax protein levels 
are markedly reduced in some tissues such as prostate 
epithelium, central and peripheral neurons, and small in- 
testine, but are not noticably perturbed in others (Miyashita 
et al., 1994a). Thus, tissue-specific factors appear to influ- 
ence the extent to which p53 is required for basal expres- 
sion of bax in vivo. It may be of relevance in this regard 
that four CACGTG motifs are located within the 5'UTR of 
the bax gene. This hexameric DNA sequence has been 
shown to represent a potential binding site for several tran- 
scription factors, including Myc, its homologs (Blackwood 
and Eisen man, 1991 ; Zervos et al., 1993; Ayer et al., 1993), 
and upstream stimulatory factor, a ubiquitously expressed 
transcription factor the activity of which is controlled by 
redox mechanisms (Pognonec et al., 1992). Given that 
Myc has been reported to induce apoptosis under some 
circumstances (Asken et al., 1991; Evan et al., 1992; Bis- 
sonnette et al., 1992), it will be important in the future to 
determine whether Myc is an additional transactivator of 
bax and whether this accounts for the ability of Myc to 
induce apoptosis. 
Experimental Procedures 
Library Screening 
A human placental DNA library in the cosmid vector pWE15 (Stra- 
tagene) was screened by using a ~P-labeled mouse bax cDNA (Miya- 
shita et al., 1994a). One of the resulting cosmid clones, pTM597-2, 
was digested with BamHI, producing a - 4000-bp fragment (containing 
the bax gene promoter) that was subcloned into pBluescript SKII (Stra- 
tagene). This generated the plasmid pTM-604-4, which was se- 
quenced. 
CAT Reporter Gene Plasmids 
A 371-bp SmaI-Sacl fragment (bax, -316 bp to -687 bp) from 
pTM604-4 was subcloned into the Hindlll site of the promoterless CAT 
plasmid, pUCSVOCAT, by blunt-end ligation, which produced the plas- 
mid pTM667-3. A 94-bp DdeI-Ddel fragment (bax, -415 bp to -508 
bp) from pTM604-4 was subcloned by blunt-end ligation into the Bglll 
site of the minimal promoter CAT reporter plasmid pA10CATBS, which 
contains an SV-40 early-region promoter in which the enhancer was 
deleted to produce the plasmid pTM672-6 (Spalholz et al., 1987). 
Oligon u cleotides 5'-GATCTCACAAGTTAGAGACAAG CCTG-3' (oligo- 
mer A) and 5'-TCGACAGGCTTGTCTCTAACTTGTGA-3' (oligomer B), 
corresponding to bax sequences from -464 bp to -486 bp, were an- 
nealed to produce a double-stranded DNA fragment hat was sub- 
cloned into the Bglll and Sail sites of pAl 0CATBS, producing pTM672- 
14. The plasmid pTM672-18 was similarly produced by annealing the 
oligomers 5'-GATCGAGACCAAGCCTGGGCGTGGGCTATATTG-3' 
(oligomer C) and 5'-TCGACAATATAGCCCACGCCCAGGCTTGT- 
CTC-3' (oligomer D), corresponding to bax from -448 bp to -475 bp. 
To create a reporter gene plasmid containing nucleotides -448 bp to 
-486 bp of bax, the oligomers A and D were annealed, filled in with 
Klenow fragment in the presence of dNTPs, and treated with T4 DNA 
kinase and ATP, and then the resulting fragment was subcloned into 
the Bglll site of pA10CATBS by blunt-end ligation. 
A mutant version of the bax-CAT plasmid containing the 94-bp 
DdeI-Ddel fragment, with four nucleotide substitutions within the con- 
sensus p53-binding sites, was created by site-directed mutagenesis 
using a PCR overlap extension technique (Ho et al., 1989). The follow- 
ing amplification primers were used with Pfu heat-stable DNA polymer- 
ase (Stratagene) and pTM604-4 as a template: 5'-GAAGATCTGAGA- 
CGGGGTTATCTCTT-3' (Bglll site underlined); 5'-CGCGTCGACTGA- 
GTGGT! l I GTITTTT-3' (Sail site underlined); 5'-AAGTTAGAGATA- 
ATGCTGGGCGTAGG-3'; and 5'-CCTACGCCCAGCATTATCTCTAA- 
CTT-3' (mutations in bold). The final PCR product was gel purified, 
digested with Bglll and Sail, and subcloned into the Bglll and Sail 
sites of pA10CATBS to produce the plasmid pTM688-2. Introduction 
of the expected mutations was confirmed by DNA sequencing. 
Transfections and Reporter Gene Assays 
Cells at - 70% confluence in 6-well ( -  35 ram) plates were transfected 
using 30 p_g of lipofectin (GIBCO BRL), 3 )~g of CAT reporter gene 
plasmid, 1 I~g of pCMV-i3-gal plasmid, and 3 I~g of either pCMV- 
p53~, pCMV-p53~9, or pRc/CMV plasmid DNA for 16 hr, essentially 
as described previously (Miyashita et al., 1994b). After 48 hr, 
transfected cells were resuspended in 50 p.I of 0.25 M Tris (pH 7.8), 
subjected to three freeze-thaw cycles, and centrifuged at 16,000 × 
g for 5 min to obtain supernatants for measurements of CAT and J~-gal 
activity as described (Miyashita et al., 1994b). 
Production of p53 Proteins Using Recombinant Baculoviruses 
The plasmids pCMV-p53,t and pCMV-p53~9 were cut with Hindlll, 
the ends were filled in using Klenow fragment, and then they were 
further cut with Xbai, thus liberating the p53-coding sequences, which 
were subcloned into the baculovirus transfer vector pVL1393 Phar- 
mingen that had been digested with Sinai and Xbal. Sf9 cells were 
then cotransfected with recombinant baculovirus transfer vector DNAs 
and BaculoGold viral DNA, as recommended by the manufacturer, 
thus producing recombinant baculoviruses. For p53 production, Sf9 
cells were infected by a high-titer stock solution of recombinant bacu- 
Ioviruses at a multiplicity of infection of 10. Cells were harvested after 
-3  days and lysed in 1% NP-40, 150 mM Nacl, 5 mM EDTA, 10% 
glycerol, and 50 mM Tris (pH 8.0), containing protease inhibitors. The 
clarified cell lysates were dialyzed against electrophoretic mobility shift 
assay (EMSA) buffer. 
EMSA 
Oligomers A and D were annealed and filled in using Klenow fragment 
in the presence of [a-32P]dCTP. A similar DNA probe was prepared 
that contained four nucleotide substitutions using the oligomers 
5'-GATCTCACAATTTAGAGATAATGCTG-3, and 5'-TCGACAATA- 
TAGCCTACGCCCAGCATTATCTC-3,. Sf9 cell lysates (2 p.g of totat 
protein) containing wild-type p53, p53(179), or no p53 protein were 
preincubated in some cases with monoclonal anti-p53 antibodies (a 
combination of 0.5 p~g of DO-1 [Santa Cruz Biotechnology] and 0.5 
p~g of Pab421 [Oncogene Science]), and then they were incubated for 
10 rain at -25°C with 0.6 I~g of sonicated salmon sperm DNA and 7 
~1 of EMSA buffer (20 mM HEPES [pH 7.5], 0.1 M NaCI, 1.5 mM MgCIz, 
10 mM dithiothreitel, 20% glycerol, 0.1% Triton X-100, I mM PMSF, 
10 ~g/ml pepstatin, 10 p.g/ml leupeptin). The 3~P-labeled double-strand 
oligomers (4 x 105 cpm) were then added. After 20 rain at -25°C, 
the samples were subjected to electrophoresis in native 4% polyacryl- 
Cell 
298 
amide gels using 1 x TBE. The gels were then dried and exposed to 
X-ray film (XAR; Kodak) at -80°C with intensifying screens. 
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